

FOOD AND DRUG ADMINISTRATION

Center for Biologics Evaluation and Research
113th Meeting of the Blood Products Advisory Committee
FDA White Oak Campus, Building 31, the Great Room (Rm. 1503)
10903 New Hampshire Ave., Silver Spring, MD, 20993
June 20, 2016

DRAFT AGENDA

Monday, June 20, 2016

Time	Presentation/ Presenter
9:30 a.m.	Call to Order and Opening Remarks Introduction of Committee Susan Leitman, M.D. Acting Chair, BPAC Recognition of Retiring Members Peter Marks, M.D., Ph.D. Director, CBER, FDA Conflict of Interest Statement Bryan Emery, LCDR Designated Federal Officer, BPAC
	Topic I: Review of the Research Programs in the Laboratory of Plasma Derivatives, Division of Hematology Research and Review, OBRR
9:40 a.m.	Overview of CBER Research Programs Carolyn Wilson, Ph.D. CBER, FDA
9:50 a.m.	Overview of OBRR Research Programs CD Atreya, Ph.D. OBRR, FDA
10:00 a.m.	Overview of the Division of Hematology Research and Review Research Programs Basil Golding, M.D. OBRR, FDA
10:10 a.m.	Overview of the Laboratory of Plasma Derivatives Dorothy Scott, M.D. OBRR, FDA
11:00 a.m.	Questions for the Speakers
11:15 a.m.	Break
11:20 a.m.	Open Public Hearing
12:20 p.m.	Closed Committee Discussion
1:00 p.m.	Adjournment